Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory
European Journal of Pharmaceutics and Biopharmaceutics · 2023-10 · 191 · 57-67
DOI: 10.1016/j.ejpb.2023.08.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023-10. Verfasst von Annick Gervais und 16 weiteren Autor:innen. Beteiligte Einrichtung: Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium. Electronic address: annick.gervais@ucb.com. Hauptthemen laut MEDLINE: Laboratories, Drug Industry. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Multi-attribute methods employing mass spectrometry are applied throughout the biopharmaceutical industry for product and process characterization purposes but are not yet widely accepted as a method for batch release and stability testing under the good manufacturing practice (GMP) regime, due to limited experience and level of comfort with the technical, compliance and regulatory aspects of its implementation at quality control (QC) laboratories. This article is the second part of a two-tiered publication aiming at providing guidance for implementation of the multi-attribute method by peptide mapping liquid chromatography mass spectrometry (MAM) in a QC laboratory. The first part [1] focuses on technical considerations, while this second part provides considerations related to GMP compliance and regulatory aspects. This publication has been prepared by a group of industry experts representing 14 globally acting major biotechnology companies under the umbrella of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Manufacturing & Quality Expert Group (MQEG).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium. Electronic address: annick.gervais@ucb.com.
- Analytical Development and Quality Control, Byondis, Microweg 22, 6545 CM, Nijmegen, the Netherlands.
- Biologics Analytical Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland.
- Biologics Drug Product Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland.
- Biological Characterisation Product Development Sciences, UCB, 216 Bath Road, Slough SL1 3WE, UK.
- Analytical Development & Innovation NBE, Merck Serono S.p.A, Via Luigi Einaudi, 11, 00012 Guidonia Montecelio - Rome, Italy.
Zitieren
APA
Gervais, A., Dirksen, E. H. C., Pohl, T., Bechtold-Peters, K., Burkitt, W., D'Alessio, V., Greven, S., Lennard, A., Li, X., Lössner, C., Niu, B., Reusch, D., O'Riordan, T., Shearer, J. W., Spencer, D., Xu, W., & Yi, L. (2023). Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory. European Journal of Pharmaceutics and Biopharmaceutics, 191, 57-67. https://doi.org/10.1016/j.ejpb.2023.08.008
Vancouver
Gervais A, Dirksen EHC, Pohl T, Bechtold-Peters K, Burkitt W, D'Alessio V, et al. Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory. European Journal of Pharmaceutics and Biopharmaceutics. 2023;191:57-67. doi:10.1016/j.ejpb.2023.08.008
BibTeX
@article{Gervais2023,
author = {Gervais, Annick and Dirksen, Eef H C and Pohl, Thomas and Bechtold-Peters, Karoline and Burkitt, Will and D'Alessio, Valerio and Greven, Simone and Lennard, Andrew and Li, Xue and Lössner, Christopher and Niu, Ben and Reusch, Dietmar and O'Riordan, Tomás and Shearer, Justin W and Spencer, David and Xu, Wei and Yi, Linda},
title = {Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
volume = {191},
pages = {57--67},
doi = {10.1016/j.ejpb.2023.08.008}
}
EUVIMED